The Age-related Macular Degeneration (AMD) Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Eylea, Lucentis, Beovu, Others), By Disease Type (Dry AMD, Wet AMD), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy).
The Age-related Macular Degeneration (AMD) Market is witnessing notable growth, driven by the aging population and the increasing prevalence of AMD, a leading cause of vision loss in older adults. This market includes pharmaceuticals and therapies aimed at managing and treating AMD, which affects the macula of the eye. Manufacturers are developing innovative therapies, including anti-VEGF (vascular endothelial growth factor) drugs and gene therapies, to address different stages of AMD. With the continuous advancement in AMD treatment options and the rising awareness of vision health, the Age-related Macular Degeneration Market is poised for sustained expansion, offering hope for improved outcomes and vision preservation for individuals affected by this progressive eye condition.
The most prominent trend in the Age-related Macular Degeneration (AMD) Market is the continual advancements in anti-VEGF (Vascular Endothelial Growth Factor) therapies and innovative treatment modalities. As the understanding of AMD mechanisms evolves, there is a notable trend towards the development of next-generation therapies that target specific pathways associated with disease progression. The market is witnessing a surge in research and development activities focused on novel anti-VEGF agents, sustained-release drug delivery systems, and gene therapies, reflecting the industry's commitment to advancing treatment options for AMD. This trend represents a shift towards more targeted and effective interventions, offering hope for improved outcomes in the management of AMD.
A major driver propelling the Age-related Macular Degeneration (AMD) Market is the growing aging population and the subsequent increase in disease prevalence. AMD is more prevalent in individuals over the age of 50, and as the global population ages, the incidence of AMD is expected to rise significantly. The demographic shift towards an older population contributes to the expanding patient pool seeking effective treatments for AMD. This demographic driver underscores the critical need for continued research, development, and commercialization of therapeutic interventions to address the rising healthcare burden associated with age-related macular degeneration.
An emerging opportunity in the Age-related Macular Degeneration (AMD) Market lies in the expansion of personalized medicine approaches. Market players have the potential to leverage advancements in genetic testing and biomarker identification to tailor AMD treatments based on individual patient profiles. This opportunity involves developing therapies that consider genetic variations, disease subtypes, and patient-specific characteristics to optimize treatment outcomes. The move towards personalized medicine in AMD opens avenues for innovative therapeutic strategies, including gene-based therapies and precision medicine approaches, allowing companies to position themselves at the forefront of delivering more targeted and customized solutions for individuals affected by AMD.
By Product
By Disease Type
By Distribution Channel
By Region
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Age-related Macular Degeneration (AMD) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Age-related Macular Degeneration (AMD) Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 INTRODUCTION TO 2024 Age-related Macular Degeneration (AMD) Markets
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 RESEARCH METHODOLOGY
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 EXECUTIVE SUMMARY
3.1 Global Age-related Macular Degeneration (AMD) Market Size Outlook, $ Million, 2021 to 2030
3.2 Age-related Macular Degeneration (AMD) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Age-related Macular Degeneration (AMD) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Age-related Macular Degeneration (AMD) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Age-related Macular Degeneration (AMD) Market Outlook by Key Countries, $ Million, 2021 to 2030
4 MARKET DYNAMICS
4.1 Key Driving Forces of Age-related Macular Degeneration (AMD) Market Industry
4.2 Key Market Trends in Age-related Macular Degeneration (AMD) Market Industry
4.3 Potential Opportunities in Age-related Macular Degeneration (AMD) Market Industry
4.4 Key Challenges in Age-related Macular Degeneration (AMD) Market Industry
5 MARKET FACTOR ANALYSIS
5.1 Competitive Landscape
5.1.1 Global Age-related Macular Degeneration (AMD) Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 GROWTH OUTLOOK ACROSS SCENARIOS
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 GLOBAL Age-related Macular Degeneration (AMD) Market OUTLOOK BY SEGMENTS
7.1 Age-related Macular Degeneration (AMD) Market Outlook by Segments
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
8 NORTH AMERICA Age-related Macular Degeneration (AMD) Market ANALYSIS AND OUTLOOK TO 2030
8.1 Introduction to North America Age-related Macular Degeneration (AMD) Markets in 2024
8.2 North America Age-related Macular Degeneration (AMD) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Age-related Macular Degeneration (AMD) Market size Outlook by Segments, 2021-2030
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
9 EUROPE Age-related Macular Degeneration (AMD) Market ANALYSIS AND OUTLOOK TO 2030
9.1 Introduction to Europe Age-related Macular Degeneration (AMD) Markets in 2024
9.2 Europe Age-related Macular Degeneration (AMD) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Age-related Macular Degeneration (AMD) Market size Outlook by Segments, 2021-2030
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
10 ASIA PACIFIC Age-related Macular Degeneration (AMD) Market ANALYSIS AND OUTLOOK TO 2030
10.1 Introduction to Asia Pacific Age-related Macular Degeneration (AMD) Markets in 2024
10.2 Asia Pacific Age-related Macular Degeneration (AMD) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Age-related Macular Degeneration (AMD) Market size Outlook by Segments, 2021-2030
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
11 SOUTH AMERICA Age-related Macular Degeneration (AMD) Market ANALYSIS AND OUTLOOK TO 2030
11.1 Introduction to South America Age-related Macular Degeneration (AMD) Markets in 2024
11.2 South America Age-related Macular Degeneration (AMD) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Age-related Macular Degeneration (AMD) Market size Outlook by Segments, 2021-2030
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
12 MIDDLE EAST AND AFRICA Age-related Macular Degeneration (AMD) Market ANALYSIS AND OUTLOOK TO 2030
12.1 Introduction to Middle East and Africa Age-related Macular Degeneration (AMD) Markets in 2024
12.2 Middle East and Africa Age-related Macular Degeneration (AMD) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Age-related Macular Degeneration (AMD) Market size Outlook by Segments, 2021-2030
By Product
Eylea
Lucentis
Beovu
Others
By Disease Type
Dry AMD
Wet AMD
By Distribution Channel
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
13 COMPANY PROFILES
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc.
Adverum Biotechnologies Inc.
Alimera Sciences Inc.
Alkeus Pharmaceuticals Inc.
Amgen Inc.
Apellis Pharmaceuticals Inc.
Bausch Health Companies Inc.
Bayer AG
Bio Thera Bio Pharmaceutical Co. Ltd.
Biocon Ltd.
F. Hoffmann La Roche Ltd.
IVERIC bio Inc.
Lupin Ltd.
Novartis AG
Outlook Therapeutics Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Ribomic Inc.
Viatris Inc.
Xbrane Biopharma AB
14 APPENDIX
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
By Disease Type
By Distribution Channel
By Region
The global Age-related Macular Degeneration (AMD) Market is one of the lucrative growth markets, poised to register a 10.1 growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AbbVie Inc., Adverum Biotechnologies Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Bio Thera Bio Pharmaceutical Co. Ltd., Biocon Ltd., F. Hoffmann La Roche Ltd., IVERIC bio Inc., Lupin Ltd., Novartis AG, Outlook Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Ribomic Inc., Viatris Inc., Xbrane Biopharma AB
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume